EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses

Yuko Murashima, Shun Yamamoto, Toshiharu Hirose, Toru Kadono, Go Ikeda, Akihiro Ohara, Mai Itoyama, Kazuki Yokoyama, Yoshitaka Honma, Koshiro Ishiyama, Jyunya Oguma, Hiroyuki Daiko und 1 weitere

Journal of Gastrointestinal Cancer · 2024

DOI: 10.1007/s12029-024-01092-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Gastrointestinal Cancer, 2024. Verfasst von Yuko Murashima und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Hauptthemen laut MEDLINE: Nivolumab, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Salvage Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivolumab monotherapy is the standard second-line treatment for advanced esophageal squamous cell carcinoma (ESCC) after failure of platinum-based chemotherapy without anti-PD-1 antibody. Fixed dosing with 240 mg every 2 weeks was approved initially, followed by fixed dosing with 480 mg every 4 weeks based on pharmacokinetics data. However, information on the comparative efficacy and safety of the two doses remains limited.

Methods

We compared progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and the incidence of adverse events (AEs) between the two doses in 117 patients who received second-line ( n = 85) or later-line ( n = 32) nivolumab monotherapy at our institution between January 2016 and December 2021.

Results

In the second-line group, patient characteristics for the 240 mg and 480 mg groups were as follows (240 mg vs. 480 mg): performance status (PS) 0/1/2 was 34/61/5% vs. 54/42/4%, and prior fluoropyrimidine plus platinum therapy (FP) was 81.3% vs. 42.3%. In the later-line group, the characteristics were: PS 0/1/2 was 28/60/12% vs. 14/86/0%, and prior FP was 60.0% vs. 42.8%. ORR was 11.9 vs. 24.0% in the second-line group ( p = 0.19) and 0 vs. 14.3% in the later-line group ( p = 0.22). Median PFS was 1.7 vs. 4.1 months on second-line (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.35–1.01, p = 0.056) and 1.4 vs. 1.8 months on later-line (HR 0.58, 95% CI 0.23–1.46, p = 0.25); AEs of any grade were observed in 58.3 vs. 69.7%, respectively.

Conclusions

The efficacy and safety of the two doses of nivolumab monotherapy were comparable in patients with advanced ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsSalvage TherapyHumansMaleFemaleMiddle AgedAgedAdultRetrospective StudiesAntineoplastic Agents, ImmunologicalAged, 80 and overProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

ChemotherapyEsophageal cancerEsophageal squamous cell carcinomaNivolumab

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Department of Gastroenterology, St. Luke's International Hospital, Tokyo, Japan.
  • Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
  • Department of Gastroenterology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
  • Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.

Zitieren

APA

Murashima, Y., Yamamoto, S., Hirose, T., Kadono, T., Ikeda, G., Ohara, A., Itoyama, M., Yokoyama, K., Honma, Y., Ishiyama, K., Oguma, J., Daiko, H., & Kato, K. (2024). Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01092-w

Vancouver

Murashima Y, Yamamoto S, Hirose T, Kadono T, Ikeda G, Ohara A, et al. Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses. Journal of Gastrointestinal Cancer. 2024. doi:10.1007/s12029-024-01092-w

BibTeX
@article{Murashima2024,
  author = {Murashima, Yuko and Yamamoto, Shun and Hirose, Toshiharu and Kadono, Toru and Ikeda, Go and Ohara, Akihiro and Itoyama, Mai and Yokoyama, Kazuki and Honma, Yoshitaka and Ishiyama, Koshiro and Oguma, Jyunya and Daiko, Hiroyuki and Kato, Ken},
  title = {Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses},
  journal = {Journal of Gastrointestinal Cancer},
  year = {2024},
  doi = {10.1007/s12029-024-01092-w}
}
Kostenlos starten →